Sickle Cell Disease Treatment Market, By Treatment Modality (Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea, Branded Products {Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYNDN (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, and FT-4202})), By End-Users (Hospitals, Specialty Clinics, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Sickle Cell Disease Treatment Market was valued at US$ 3.3 Billion in 2024 and is projected to grow at a CAGR of 10.1% to reach US$ 7.8 Billion by 2034.

[PDF] Sickle Cell Disease Treatment Market is an inherited red blood cell disorders which affect hemoglobin that carries oxygen through body. Fatigue and shortness of breath are the main symptoms of sickle cell disease which can be fatal lead to organ damage and blocks flow of blood to organs. Stem cell and bone marrow transplant are the current treatment to cure Sickle Cell Disease.

Rising incidence of sickle cell disease has become the major contribution in target market growth. Further, according to CDC (Centers for Disease Control and Prevention), in United States (in 2022) the Sickle Cell Disease affects approx. 100,000 Americans, occurs among 1 out of every 365 Black or African-American births and around 1 in 13 Black or African-American babies are born with SCT (Sickle Cell Treat). Furthermore, emergence of new treatment in treating SCD is anticipated to boost the demand for Sickle Cell Disease Treatment market growth.

Rising incidence of SCD and demand for effective treatment

Rising incidence for SCD (Sickle Cell Disease) and demand for effective treatment has become the major factor in Sickle Cell Disease Treatment market growth. Further, according to CDC (Centers for Disease Control and Prevention), Sickle Cell Disease occurs among 1 out of every 16,300 Hispanic-American births. For instance, in 2022, according to PMC (PubMed Central), Sickle Cell Disease affect around 100,000 persons in U.S. with multiple complications and reduction in life expectancy. Furthermore, rising awareness of disease severity among individuals has given rise in demand for effective treatment procedures which has further facilitated the target market growth.

Emergence of new treatment modalities

Emergence of new treatment modalities has given positive impact on target market growth. Major players has increased their focus on launch of new products which has further facilitated the target market growth. For instance, in 2017, FDA (Food and Drug Administration) has approved Emmaus Life Sciences drug Endari for SCD patients who are aged around five years and old. After launch of Endari few more key players such as Oxbryta (Global Blood therapeutics), Zynteglo (bluebird bio Inc.), Adakveo (Novartis) and PYRUKYND (Agios Pharmaceuticals Inc.), emerged in market with launch of new products which is expected to fuel the demand for Sickle Cell Disease Treatment market growth.

Restrains:

However, slow adoption of treatments due to cost associated with it, absence of a permanent cure for this disease and complications associated with the treatment and high cost of drug has hampered the Sickle Cell Disease Treatment market growth.

Sickle Cell Disease Treatment Market is segmented based on Treatment Modality, End-User and Region.

Based on the Treatment Modality, Sickle Cell Disease Treatment market is segmented into the Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea, Branded Products {Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYNDN (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, and FT-4202})),Based on End-Users, the global market is classified into Hospitals, Specialty Clinics, and Others.

Regional Insights:

On the basis of region the Sickle Cell Disease Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to rising prevalence of SCD (Sickle Cell Disease), potential pipeline candidates, rising collaborations to improve treatment of disease, robust healthcare infrastructure and strong government initiative is anticipated to increase demand for Sickle Cell Disease Treatment in the region.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Sickle Cell Disease Treatment Market report based on Treatment Modality, End-Users and Region:

Sickle Cell Disease Treatment Market, By Treatment Modality:

• Bone Marrow Transplant
• Blood Transfusion
• Pharmacotherapy: 
  • Hydroxyurea
• Branded Products:
  • Endari
  • Adakveo
  • Oxbryta
  • Zynteglo
  • PYRUKYNDN (Mitapivat)
  • CTX001
  • Inclacumab
  • MGTA-145
  • Vamifeport (VIT-2763)
  • ALXN1820
  • FT-4202

Sickle Cell Disease Treatment Market, By End-Users:

• Hospitals
• Specialty Clinics
• Others

Sickle Cell Disease Treatment Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

Recent Development:

• In October 2022, Pfizer has completed the acquisition of Global Blood Therapeutics. This acquisition will bring the leading sickle cell disease portfolio & pipeline to Pfizer with potential for addressing critical needs in an underserved patient community. This acquisition will help in accelerating innovation, by expeditiously bringing multiple potential best-in-class treatment to people who are living with sickle cell disease.
• In September 2022, with rare acquisition, Novo Nordisk has made $1B bet on sickle cell disease drug. Novo Nordisk will spend $1.1 billion for acquiring Forma Therapeutics. This deal will reflect drug makers by continuing interest in sickle cell disease and related rare blood disorders.
• In April 2022, Emmaus Life Sciences has launched Full Service Telehealth Solution. This newly launched Telehealth solution in U.S. will afford patients and providers an online access to ‘Endari’ a company’s new prescription grade L-glutamine oral powder for treating sickle cell disease.

The key players operating the Sickle Cell Disease Treatment Market includes, Baxter, Bluebird Bio, Bristol-Myers Squibb Company, Eli Lilly, Global Blood Therapeutics, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Mast Therapeutics, Novartis AG, Pfizer, Inc., Sanofi and others.

• Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Baxter
• Bluebird Bio
• Bristol-Myers Squibb Company
• Eli Lilly
• Global Blood Therapeutics
• Gilead Sciences, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Mast Therapeutics
• Novartis AG
• Sanofi

“*” marked represents similar segmentation in other categories in the respective section